Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 798–799 (2007)Cite this article

boxed-textNissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pogue J and Yusuf S (1998) Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 351: 47–52

    Article  CAS  Google Scholar 

  2. Home PD et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 357: 28–38

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. HC Gerstein is the Director of the Division of Endocrinology and Metabolism and S Yusuf is the Director of the Population Research Institute, McMaster University Hamilton, ON, Canada.,

    Hertzel C Gerstein & Salim Yusuf

Authors
  1. Hertzel C Gerstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salim Yusuf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hertzel C Gerstein.

Ethics declarations

Competing interests

The authors have acted as consultants and/or received research support from the following companies: Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cadila Pharmaceuticals, Eli Lilly, GlaxoSmithKline, King Pharmaceuticals, Merck, Novo Nordisk, Organon, Sanofi-Aventis, and Takeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerstein, H., Yusuf, S. Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?. Nat Rev Endocrinol 3, 798–799 (2007). https://doi.org/10.1038/ncpendmet0640

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0640

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing